PSNL:NASDAQ, Personalis, Inc.
PSNL stock overview
Personalis, Inc. (PSNL:NASDAQ) closed at $14.80 on November 16, 2026,
down 5.79% on the day.
The stock trades 21.7% below its 52-week high of $18.89
and 198.7% above its 52-week low of $4.96.
Over the past year, it gained 97.9%.
Personalis, Inc. is part of the Health Care sector (Medical Specialities).
Key figures
- Price
- $14.80
- Day change
- -5.79%
- Volume
- 6,272,680
- Average volume
- 2,727,892
- Market cap
- 1B+
- 52-week range
- $4.96 – $18.89
- 50-day average
- $16.08
- 200-day average
- $11.57
Price action over the past year
In 252 trading sessions since November 14, 2025, PSNL closed higher on 130 days (52%).
Its best day was November 21, 2025 (+17.51%) and its worst was March 12, 2026 (-17.11%).
The stock moved 10% or more in a single session 17 times.
It opened at least 5% above the previous day's high 3 times.
Recent signals
PSNL news
-
Nov 11, 2026:
Are DAN, GPRO, PSNL Obtaining Fair Deals for their Shareholders?
-
Nov 9, 2026:
Cancer Immunotherapy Drug Discovery Outsourcing - Global Strategic Business Report 2026: Capitalize on 13.5% CAGR to $2.4 Billion by 2032 Featuring Covance, Crown Bioscience, Personalis and Promega
-
Nov 7, 2026:
Did Wider Losses Just Shift Personalis (PSNL) Stock Investment Narrative?
-
Nov 4, 2026:
Personalis: Q3 Earnings Snapshot
-
Nov 4, 2026:
Personalis Reports Third Quarter Results
-
Nov 3, 2026:
TEM Q3 Earnings Call Highlights Growth and 2027 Pricing Upside
-
Nov 3, 2026:
How Long Can GRAIL Keep Burning Cash?
-
Nov 2, 2026:
Do You Own Tempus AI Without Knowing It? Check These ETFs After Its Earnings Surge
About Personalis, Inc.
Personalis Inc is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies.
Similar stocks
Find more stocks like PSNL with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.